In this video, Motley Fool health-care analyst David Williamson talks about some of the biggest investing stories in the health-care space today. He tells us about Pfizer (NYSE: PFE) and Bristol-Myers Squibb's (NYSE: BMY) latest European victory, a major insurance win for obesity-drug maker VIVUS (NASDAQ:VVUS), a huge vote of share-price confidence for Sarepta (NASDAQ: SRPT) and its drug for Duchenne muscular dystrophy, and a big tumble for St. Jude Medical (NYSE: STJ) after another problem with one of its products.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Everything You Need to Know: Pfizer, Bristol-Myers Squibb, VIVUS, Sarepta, and St. Jude
NYSE: PFE
Pfizer

Motley Fool analyst David Williamson takes us through some major health-care jumps and tumbles.
Brenton Flynn owns shares of Sarepta Therapeutics. David Williamson owns shares of Pfizer. The Motley Fool owns shares of St. Jude Medical. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned





*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.